FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Leading Causes of Drug Recalls

[ Price : $8.95]

CDERs Joseph Famulare cites recent statistics on drug recalls, and identifies specific problem areas in production and quality sys...

MDS Pharma Research Studies Faulted Again by FDA

[ Price : $8.95]

A scathing FDA untitled letter provides a glimpse into the troubles contract research organization MDS Pharma is having in trying ...

FDA Plans Follow-up Audit of Medtronic GMP Woes

[ Price : $8.95]

FDA plans a follow-up inspection of a Medtronic neurological devices manufacturing facility after the agency received limited info...

Sue FDA with Me, Levothyroxine Impurities Fighter Asks USP

[ Price : $8.95]

Retired FDA chemist Burton Appleton asks USP to help him appeal last months federal court loss to FDA on levothyroxine documents, ...

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Actavis Totowa, Frye Health Systems, Hamricks, LGS Technologies, Medtronic, and ...

Guidance on Drug Interaction Studies

[ Price : $8.95]

Federal Register Notice: FDA releases a draft guidance on drug interaction studies, which details study design and implications fo...

Mylan Gains Approval for Generic Topamax

[ Price : $8.95]

FDA approves a Mylan Pharmaceuticals ANDA for topiramate tablets, 25 mg, 100 mg and 200 mg, a generic version of Ortho-McNeil's To...

FDA OKs KV Pharmas Generic Tiazac

[ Price : $8.95]

FDA approves a KV Pharmaceutical Co. ANDA for a generic copy of Forest Pharmaceuticals calcium channel blocker Tiazac in six dosag...

Graham Criticizes Mercks Development of Arcoxia

[ Price : $8.95]

In a just-posted JAMA editorial, FDA whistleblower David Graham questions Mercks decision to pursue approval of its next generatio...